Sitagliptin Improves Glycemic Profile In Type 2 Diabetes Mild Renal Impairment | Latest News RSS feed

Sitagliptin Improves Glycemic Profile In Type 2 Diabetes Mild Renal Impairment - Latest News


Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)

“These studies further support the clinical profile of JANUVIA ... Safety and Efficacy of Sitagliptin Compared with Dapagliflozin in Subjects with Type 2 Diabetes, Mild Renal Impairment and Inadequate ... read more

FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults

Dapagliflozin is being reviewed by the FDA for use as monotherapy, and in combination with other antidiabetic agents, as an adjunct to diet and exercise to improve glycemic control in adults with type ... read more

Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes

This article provides an overview of the role of the kidney in type 2 diabetes ... sitagliptin. These data show that canagliflozin may provide efficacy in triple therapy without an added risk of hypog... read more

Looking for another news?


Obstructive sleep apnea may worsen diabetes

Obstructive Sleep Apnea (OSA ... the severity of OSA may improve glycemic control," said Dr. Aronsohn. "Thus effective treatment of OSA may represent a novel and non-pharmacologic intervention in the ... read more


Ozempic® approved in Canada for the treatment of adults with type 2 diabetes

as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, when metformin is not tolerated or contraindicated. 1 Ozempic ®, a once-weekly glucagon-like pep... read more

Best Treatments for Type 2 Diabetes

Type 2 diabetes is one ... people who diagnosed with diabetes get the medical care, including drugs, that are proved effective. Diabetes also raises the risk for a host of other problems. These includ... read more

The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?

Diabetic nephropathy is the leading cause of end-stage renal disease worldwide ... lowering drugs used in the treatment of type 2 diabetes mellitus (T2DM). Therapeutic agents from these two drug class... read more

Janssen Research & Development to Present Results from Five Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

The kidneys of people with type 2 diabetes ... moderate renal impairment and inadequate glycemic control with diet and exercise, will be presented in the poster presentation “Canagliflozin, a Sodium G... read more

Very-low-carb diet shows promise in type 1 diabetes

Very-low-carbohydrate diets can improve ... type 1 diabetes, primarily that they increase the risk of hypoglycemia, or dangerous drops in blood sugar. However, in the study, rates of hospitalization f... read more

Diabetes Treatment, Part 2: Oral Agents for Glycemic Management

3 Because of metformin's relatively good safety profile, association with weight loss or weight neutrality, and availability as a generic formulation, it is commonly used as an initial agent in type 2 ... read more

Ozempic® approved in Canada for the treatment of adults with type 2 diabetes

as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, when metformin is not tolerated or contraindicated. 1 Ozempic ®, a once-weekly glucagon-like pep... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us